[{"id":"640096cd-c7c9-4654-ac34-5436622e9392","acronym":"","url":"https://clinicaltrials.gov/study/NCT02869633","created_at":"2021-01-18T14:05:18.356Z","updated_at":"2024-07-02T16:35:32.127Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant","source_id_and_acronym":"NCT02869633","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" NOTCH mutation","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-10-23"},{"id":"35ab7548-637e-4229-8bfc-9998c89fa4e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01653470","created_at":"2021-01-18T07:07:38.583Z","updated_at":"2024-07-02T16:36:50.836Z","phase":"Phase 1","brief_title":"Study to Evaluate Safety \u0026 Tolerability of BMS-906024 in Combination With Chemotherapy \u0026 to Define DLTs \u0026 MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors","source_id_and_acronym":"NCT01653470","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" HES1","pipe":" | ","alterations":" NOTCH mutation","tags":["HES1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • 5-fluorouracil • irinotecan • leucovorin calcium • AL101 • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 10/12/2012","start_date":" 10/12/2012","primary_txt":" Primary completion: 05/03/2017","primary_completion_date":" 05/03/2017","study_txt":" Completion: 05/08/2017","study_completion_date":" 05/08/2017","last_update_posted":"2020-01-28"},{"id":"ffc3eeaf-0c0b-4248-ac40-a4e3ffc99220","acronym":"","url":"https://clinicaltrials.gov/study/NCT02518113","created_at":"2021-01-18T12:10:07.428Z","updated_at":"2024-07-02T16:36:55.784Z","phase":"Phase 1b","brief_title":"A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL","source_id_and_acronym":"NCT02518113","lead_sponsor":"Eli Lilly and Company","biomarkers":" NOTCH1 • FBXW7","pipe":" | ","alterations":" FBXW7 mutation • NOTCH mutation","tags":["NOTCH1 • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FBXW7 mutation • NOTCH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • crenigacestat (LY3039478)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 01/15/2018","primary_completion_date":" 01/15/2018","study_txt":" Completion: 01/15/2018","study_completion_date":" 01/15/2018","last_update_posted":"2019-09-11"}]